Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study
Abstract Background This pilot trial aimed to investigate whether modified short-term fasting (mSTF) reduces the incidence of chemotherapy-induced toxicities and whether an initial ketogenic diet (KD) as fasting supportive diet reduces fasting-related discomfort and improves the compliance. Methods...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07041-7 |
id |
doaj-800035a0bc82415c82a6ac9a0a372d98 |
---|---|
record_format |
Article |
spelling |
doaj-800035a0bc82415c82a6ac9a0a372d982020-11-25T02:51:23ZengBMCBMC Cancer1471-24072020-06-0120111410.1186/s12885-020-07041-7Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot studyStefanie Zorn0Janine Ehret1Rebecca Schäuble2Beate Rautenberg3Gabriele Ihorst4Hartmut Bertz5Paul Urbain6Anna Raynor7Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgDepartment of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgDepartment of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgDepartment of Gynecology and Gynecologic Oncology, Medical Center – University of Freiburg, Faculty of Gynecology, University of FreiburgClinical Trials Unit, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgDepartment of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgDepartment of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgDepartment of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of FreiburgAbstract Background This pilot trial aimed to investigate whether modified short-term fasting (mSTF) reduces the incidence of chemotherapy-induced toxicities and whether an initial ketogenic diet (KD) as fasting supportive diet reduces fasting-related discomfort and improves the compliance. Methods In this controlled cross-over trial, gynaecologic cancer patients undergoing chemotherapy with a minimum of 4 cycles fasted for 96 h during half of their chemotherapy cycles and consumed a normocaloric diet during the other chemotherapy cycles. The caloric intake during mSTF was restricted to 25% of each patient’s daily requirement. In addition, half of the patients should eat a 6-day normocaloric KD prior to each mSTF period to investigate a KD’s hunger-suppression effect. Chemotherapy-induced toxicities, fasting-related discomfort, body composition, quality of life, laboratory values, and compliance were assessed at each chemotherapy. Results Thirty patients aged 30–74 years (median 54 years) completed the study. During mSTF the frequency and severity score of stomatitis [− 0.16 ± 0.06; 95% CI -0.28 - (− 0.03); P = 0.013], headaches [− 1.80 ± 0.55; 95% CI -2.89 – (− 0.71); P = 0.002], weakness [− 1.99 ± 0.87; 95% CI -3.72 – (− 0.26); P = 0.024] and the total toxicities’ score were significantly reduced [− 10.36 ± 4.44; 95% CI -19.22 - (− 1.50); P = 0.023]. We also observed significantly fewer chemotherapy postponements post-mSTF, reflecting improved tolerance of chemotherapy [− 0.80 ± 0.37; 95% CI -1.53 – (− 0.06); P = 0.034]. A significant reduction in mean body weight by − 0.79 ± 1.47 kg during mSTF was not compensated and remained until study’s conclusion (P < 0.005). On average, Insulin [− 169.4 ± 44.1; 95% CI -257.1 – (− 81.8); P < 0.001] and Insulin-like growth factor 1 levels [− 33.3 ± 5.4; 95% CI -44.1 – (− 22.5); P < 0.001] dropped significantly during fasting. The KD as a fasting supportive diet neither reduced fasting-related discomfort nor improved compliance of our fasting regimen. Conclusion MSTF is safe and feasible in gynaecologic cancer patients. Our results indicate that mSTF during chemotherapy can reduce chemotherapy-induced toxicities and enhance the tolerance of chemotherapy. Larger clinical trials are required to recommend mSTF for cancer patients. Trial registration germanctr.de: DRKS00011610 , registered 30 January, 2017.http://link.springer.com/article/10.1186/s12885-020-07041-7Breast cancerGynaecological cancerChemotherapyFastingKetogenic dietCalorie restriction |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stefanie Zorn Janine Ehret Rebecca Schäuble Beate Rautenberg Gabriele Ihorst Hartmut Bertz Paul Urbain Anna Raynor |
spellingShingle |
Stefanie Zorn Janine Ehret Rebecca Schäuble Beate Rautenberg Gabriele Ihorst Hartmut Bertz Paul Urbain Anna Raynor Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study BMC Cancer Breast cancer Gynaecological cancer Chemotherapy Fasting Ketogenic diet Calorie restriction |
author_facet |
Stefanie Zorn Janine Ehret Rebecca Schäuble Beate Rautenberg Gabriele Ihorst Hartmut Bertz Paul Urbain Anna Raynor |
author_sort |
Stefanie Zorn |
title |
Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study |
title_short |
Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study |
title_full |
Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study |
title_fullStr |
Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study |
title_full_unstemmed |
Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study |
title_sort |
impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2020-06-01 |
description |
Abstract Background This pilot trial aimed to investigate whether modified short-term fasting (mSTF) reduces the incidence of chemotherapy-induced toxicities and whether an initial ketogenic diet (KD) as fasting supportive diet reduces fasting-related discomfort and improves the compliance. Methods In this controlled cross-over trial, gynaecologic cancer patients undergoing chemotherapy with a minimum of 4 cycles fasted for 96 h during half of their chemotherapy cycles and consumed a normocaloric diet during the other chemotherapy cycles. The caloric intake during mSTF was restricted to 25% of each patient’s daily requirement. In addition, half of the patients should eat a 6-day normocaloric KD prior to each mSTF period to investigate a KD’s hunger-suppression effect. Chemotherapy-induced toxicities, fasting-related discomfort, body composition, quality of life, laboratory values, and compliance were assessed at each chemotherapy. Results Thirty patients aged 30–74 years (median 54 years) completed the study. During mSTF the frequency and severity score of stomatitis [− 0.16 ± 0.06; 95% CI -0.28 - (− 0.03); P = 0.013], headaches [− 1.80 ± 0.55; 95% CI -2.89 – (− 0.71); P = 0.002], weakness [− 1.99 ± 0.87; 95% CI -3.72 – (− 0.26); P = 0.024] and the total toxicities’ score were significantly reduced [− 10.36 ± 4.44; 95% CI -19.22 - (− 1.50); P = 0.023]. We also observed significantly fewer chemotherapy postponements post-mSTF, reflecting improved tolerance of chemotherapy [− 0.80 ± 0.37; 95% CI -1.53 – (− 0.06); P = 0.034]. A significant reduction in mean body weight by − 0.79 ± 1.47 kg during mSTF was not compensated and remained until study’s conclusion (P < 0.005). On average, Insulin [− 169.4 ± 44.1; 95% CI -257.1 – (− 81.8); P < 0.001] and Insulin-like growth factor 1 levels [− 33.3 ± 5.4; 95% CI -44.1 – (− 22.5); P < 0.001] dropped significantly during fasting. The KD as a fasting supportive diet neither reduced fasting-related discomfort nor improved compliance of our fasting regimen. Conclusion MSTF is safe and feasible in gynaecologic cancer patients. Our results indicate that mSTF during chemotherapy can reduce chemotherapy-induced toxicities and enhance the tolerance of chemotherapy. Larger clinical trials are required to recommend mSTF for cancer patients. Trial registration germanctr.de: DRKS00011610 , registered 30 January, 2017. |
topic |
Breast cancer Gynaecological cancer Chemotherapy Fasting Ketogenic diet Calorie restriction |
url |
http://link.springer.com/article/10.1186/s12885-020-07041-7 |
work_keys_str_mv |
AT stefaniezorn impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT janineehret impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT rebeccaschauble impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT beaterautenberg impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT gabrieleihorst impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT hartmutbertz impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT paulurbain impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy AT annaraynor impactofmodifiedshorttermfastinganditscombinationwithafastingsupportivedietduringchemotherapyontheincidenceandseverityofchemotherapyinducedtoxicitiesincancerpatientsacontrolledcrossoverpilotstudy |
_version_ |
1724734928028958720 |